Overland Therapeutics Announces Oral Presentations at 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden on June 11-14, 2026.

The featured presentation will unveil first-in-human clinical data of OL-101, an autologous GPRC5D and BCMA bispecific dual targeting CAR-T for multiple myeloma. The study primarily focuses on patients post BCMA- or GPRC5D-targeted therapy or with extramedullary disease (EMD).
Further detailed information is outlined below: